MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jgh.70059

Медицинская библиотека · Journal of gastroenterology and hepatology · 2025

Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment.

Ogawa Eiichi, Kohjima Motoyuki, Koyanagi Toshimasa, Dohmen Kazufumi, Ooho Aritsune, Kawano Akira, Furusyo Norihiro, Kajiwara Eiji, Satoh Takeaki, Takahashi Kazuhiro, Azuma Koichi, Sugimoto Rie, Ichiki Yasunori, Senju Takeshi, Amagase Hiromasa, Tanaka Masatake, Nakamuta Makoto, Nomura Hideyuki, Hayashi Jun, Kyushu University Liver Disease Study (KULDS) Group

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND AND AIM: Long-term nucleos(t)ide analog (NUC) therapy is essential for chronic hepatitis B (CHB) management. However, data on long-term outcomes, particularly for patients switching to tenofovir alafenamide (TAF) and patients with chronic kidney disease (CKD), remain limited. This study aimed to evaluate the 5-year virological effectiveness and renal safety of sequential TAF therapy, with a focus on those with pre-existing CKD.

METHODS

This real-world, multicenter, retrospective study included 414 CHB patients aged ≥ 18 years who switched from a prior NUC to TAF and were followed for at least 5 years. Patients were stratified based on renal function (CKD or non-CKD) at baseline. Study endpoints included 5-year virological efficacy, biochemical and fibrosis responses, and renal function changes.

RESULTS

Among the patients, 100 (24.2%) had CKD at the time of switching to TAF. Over 5 years, HBV DNA suppression rate increased from 85.0% to 100%, HBV DNA suppression with target not detected rate rose from 74.0% to 91.0%, and alanine aminotransferase normalization rate (AASLD criteria) improved from 66.0% to 79.0%, similar to the results of patients with non-CKD. Estimated glomerular filtration rate remained stable regardless of baseline renal status or prior NUC regimen, demonstrating long-term renal safety. There were no cases of HBV DNA breakthrough, including among those previously on combination NUCs. For patients with cirrhosis, the FIB-4 index significantly improved over time (p = 0.008).

CONCLUSIONS

Sequential TAF therapy demonstrated robust virological efficacy, biochemical and fibrosis improvements, and excellent renal safety over 5 years, irrespective of baseline renal function.

Для цитирования: Ogawa Eiichi, Kohjima Motoyuki, Koyanagi Toshimasa, Dohmen Kazufumi, Ooho Aritsune, Kawano Akira, Furusyo Norihiro, Kajiwara Eiji, Satoh Takeaki, Takahashi Kazuhiro, Azuma Koichi, Sugimoto Rie, Ichiki Yasunori, Senju Takeshi, Amagase Hiromasa, Tanaka Masatake, Nakamuta Makoto, Nomura Hideyuki, Hayashi Jun, Kyushu University Liver Disease Study (KULDS) Group. Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment.. Journal of gastroenterology and hepatology. 2025. DOI: 10.1111/jgh.70059.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.